Systematic Coronary Risk Evaluation 2-Diabetes (SCORE2-Diabetes)

ورودی‌های بالینی بیمار

حداقل ۴۰ — حداکثر ۶۹ • واحد: years

حداقل ۸۰ — حداکثر ۲۵۰ • واحد: mmHg

حداقل ۲ — حداکثر ۱۲ • واحد: mmol/L

حداقل ۰.۵ — حداکثر ۳.۵ • واحد: mmol/L

حداقل ۱۸ — حداکثر ۶۹ • واحد: years

حداقل ۲۰ — حداکثر ۱۳۰ • واحد: mmol/mol

حداقل ۱۵ — حداکثر ۱۵۰ • واحد: mL/min/1.73m²

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
cvd risk
—%
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low to Moderate Risk0–2.5
  • Moderate Risk2.5–5
  • High Risk5–7.5
  • High Risk7.5–10
Direct Clinical Answer

The Systematic Coronary Risk Evaluation 2-Diabetes (SCORE2-Diabetes) calculator is designed for bedside predicting 10-year cardiovascular disease (fatal and non-fatal myocardial infarction and stroke) risk in patients with type 2 diabetes aged under 70 years without prior cardiovascular disease in clinical practice. The resulting score directly.

Clinical Guidelines & Evidence

Predicts 10-year cardiovascular disease (fatal and non-fatal myocardial infarction and stroke) risk in patients with type 2 diabetes aged under 70 years without prior cardiovascular disease.

Clinical Indication

The Systematic Coronary Risk Evaluation 2-Diabetes (SCORE2-Diabetes) is indicated for bedside clinical practice to support Predicts 10-year cardiovascular disease (fatal and non-fatal myocardial infarction and stroke) risk in patients with type 2 diabetes aged under 70 years without prior cardiovascular disease.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.

Limitations & Contraindications

In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.

Clinical Pearls & Action Plan

Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines.

Formula & Variables:

Uses Fine and Gray competing risk models with diabetes-specific variables (HbA1c, age at diagnosis, eGFR) added to conventional SCORE2 risk factors, calibrated to four European risk regions

Input Parameters

NameTypeRequiredDescription
sexstringYesBiological sex
ageintegerYesAge in years(years)
smokingstringYesCurrent smoking status
systolic_bpintegerYesSystolic blood pressure(mmHg)
total_cholesterolfloatYesTotal cholesterol(mmol/L)
hdl_cholesterolfloatYesHDL cholesterol(mmol/L)
age_diabetes_diagnosisintegerYesAge at type 2 diabetes diagnosis(years)
hba1cfloatYesGlycated hemoglobin (HbA1c)(mmol/mol)
egfrfloatYesEstimated glomerular filtration rate (eGFR)(mL/min/1.73m²)
risk_regionstringYesCardiovascular risk region based on country

Score Interpretation & Guidance

RangeStageDescription
0–2.5Low to Moderate RiskLow to moderate risk (<2.5% for age <50 years)
2.5–5Moderate RiskModerate risk (2.5-5% for age <50 years or <5% for age 50-69 years)
5–7.5High RiskHigh risk (5-7.5% for age <50 years or 5-10% for age 50-69 years)
7.5–10High RiskHigh risk (7.5-10% for age 50-69 years)
10–100Very High RiskVery high risk (≥7.5% for age <50 years or ≥10% for age 50-69 years)

Evidence-Based References (EBM)

  • SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023 Jul 21;44(28):2544-2556. doi: 10.1093/eurheartj/ehad260.DOI: 10.1093/eurheartj/ehad260
  • Pennells L, Kaptoge S, Østergaard HB, Read SH, Carinci F, Franch-Nadal J, et al. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023 Jul 21;44(28):2544-2556.
  • Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.DOI: 10.1093/eurheartj/ehab484

Related calculators